Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

VCAM-1-targeting polyelectrolyte complex enhances therapeutic efficacy of miR-92a inhibitors in vivo

Jan. 12, 2022

DiNAQOR and CMRI enter research collaboration on cardiac specific AAV capsids

Jan. 11, 2022

Tenaya expands heart disease pipeline with selection of TN-401 as development candidate

Jan. 11, 2022

MCUF-651, a GC-A PAM for the treatment of cardiovascular, renal and metabolic diseases

Jan. 5, 2022

Cardiovascular

Jan. 1, 2022

Researchers discover more than 1,300 genes linked to congenital heart disease

Dec. 20, 2021

Newly identified variant has large effects on two aspects of cardiovascular risk

Dec. 3, 2021

Guard reports preclinical data on ROSgard in animal models of sepsis

Nov. 23, 2021

Erythrocyte miR-210 as target for prevention of endothelial dysfunction in type 2 diabetes

Nov. 23, 2021

Study offers insights into post-MI fibrosis

Nov. 19, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...